Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender
- People diagnosed with HER2-positive, RAS wild-type colorectal cancer that has spread or cannot be removed by surgery, and who have already received specific prior treatments including fluoropyrimidine, oxaliplatin, irinotecan, and a type of anti-VEGF antibody therapy; people whose tumours have certain genetic features (dMMR or MSI-H) must also have received a specific type of immunotherapy beforehand
- People who have at least one tumour that can be measured on a scan
- People with a general health performance score of 0, 1, or 2 on a standard medical scale (ECOG), meaning they are fully active to moderately limited in daily activity (confirm with trial site)
- People with a life expectancy of more than 3 months
- People with adequately functioning bone marrow, liver, kidneys, and blood clotting (confirm with trial site)
- Additional inclusion criteria may apply — the trial site can provide full details
Who may not be able to join:
- People who have previously received any anti-HER2 targeted therapy
- People who have received chemotherapy or radiation therapy within 3 weeks before joining, immunotherapy within 4 weeks, or palliative (symptom-relieving) radiotherapy to non-target areas within 2 weeks before joining
- People who have taken part in another interventional clinical trial within 2 weeks before joining, or within a period based on the last dose of the trial medicine (whichever is shorter)
- People who have had major surgery (not including needle biopsies) or a significant injury within 4 weeks before joining
- People who still have unresolved side effects from previous treatments rated above a mild level (Grade 1) at the time of screening
- People with active, symptomatic cancer spread to the brain or central nervous system; people with brain metastases that cause no symptoms and have not required steroid treatment in the past 30 days may still be considered
- People who have had another cancer within the past 3 years, with some exceptions such as treated skin basal cell carcinoma, cervical carcinoma in situ, low-grade prostate cancer, or ductal carcinoma in situ of the breast
- People with an active infection that has not been brought under control at the time of screening
- Additional exclusion criteria may apply — the trial site can provide full details
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 8053009373
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose limiting toxicity, maximum tolerated dose, and recommended phase 2 dose; Objective Response Rate (ORR) by IRC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.